Jinwon Life Sciences Receives Approval to Recruit General Participants for Phase 2 Clinical Trial of 'COVID-19 Co-Spray Treatment'

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 15th that it has received approval from the IRB of the Baton Rouge Clinical Trial Center to expand the clinical trial subjects of GLS-1200, a COVID-19 infection prevention nasal spray treatment currently undergoing Phase 2 clinical trials, to the general public.

A company official stated, “The Phase 2 clinical trial of GLS-1200 is being conducted at the University of Pennsylvania Clinical Center and the Baton Rouge Clinical Center in Louisiana. The University of Pennsylvania Clinical Center has completed the registration of clinical trial subjects, and the Baton Rouge Clinical Center is currently recruiting and registering clinical trial subjects,” adding, “With this approval from the Baton Rouge Clinical Trial Center IRB, the clinical trial subjects have been expanded from healthcare workers to the general public regardless of occupation.”

He also noted, “Recently, the B.1.1.7 variant of the UK COVID-19 virus has been spreading in Baton Rouge, increasing the number of infections, which has raised local interest in the GLS-1200 product.”

The company further explained, “In previous studies using ferrets, when GLS-1200 was sprayed on the nasal area, a reduction of more than ten thousand times in the virus was confirmed around three days after COVID-19 virus infection compared to ferrets that were not treated with GLS-1200,” and added, “Currently, research is underway using hamsters, which are experimental animals for COVID-19 infection, to verify whether GLS-1200 prevents nasal infection by the South African variant of the virus.”